Literature DB >> 16155757

CXCL12-3' A polymorphism and lung cancer metastases protection: new perspectives in immunotherapy?

Ana Coelho1, Carmen Calçada, Raquel Catarino, Daniela Pinto, Graça Fonseca, Rui Medeiros.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16155757     DOI: 10.1007/s00262-005-0062-1

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


× No keyword cloud information.
  6 in total

1.  Association between SDF1-3'A or CXCR4 gene polymorphisms with predisposition to and clinicopathological characteristics of prostate cancer with or without metastases.

Authors:  Ferruh K Işman; Canan Kucukgergin; Selçuk Daşdemir; Bedia Cakmakoglu; Oner Sanli; Sule Seckin
Journal:  Mol Biol Rep       Date:  2012-10-11       Impact factor: 2.316

2.  Genetic variants of SDF-1 and CXCR4 genes in endometrial carcinoma.

Authors:  Canan Cacina; Sibel Bulgurcuoglu-Kuran; Ahmet Cem Iyibozkurt; Ilhan Yaylim-Eraltan; Bedia Cakmakoglu
Journal:  Mol Biol Rep       Date:  2011-05-24       Impact factor: 2.316

3.  CXCL12 G801A polymorphism is associated with an increased risk of benign salivary gland tumors in the Chinese population.

Authors:  Weijia Liu; Enxin Zhu; Ru Wang; Lihong Wang; Tingjiao Liu
Journal:  Med Oncol       Date:  2011-02-05       Impact factor: 3.064

4.  Single Nucleotide Polymorphisms in Genes MACC1, RAD18, MMP7 and SDF-1a As Prognostic Factors in Resectable Colorectal Cancer.

Authors:  Matej Horvat; Uros Potocnik; Katja Repnik; Rajko Kavalar; Vesna Zadnik; Stojan Potrc; Borut Stabuc
Journal:  Radiol Oncol       Date:  2016-09-08       Impact factor: 2.991

5.  CXCR4 in Cancer and Its Regulation by PPARgamma.

Authors:  Cynthia Lee Richard; Jonathan Blay
Journal:  PPAR Res       Date:  2008       Impact factor: 4.964

Review 6.  Single Nucleotide Polymorphisms as Prognostic and Predictive Factors of Adjuvant Chemotherapy in Colorectal Cancer of Stages I and II.

Authors:  Matej Horvat; Uroš Potočnik; Katja Repnik; Rajko Kavalar; Borut Štabuc
Journal:  Gastroenterol Res Pract       Date:  2016-01-14       Impact factor: 2.260

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.